BCR-ABL Major Quantitative Test sale cost 1800 AED
Periodontal Multiplex Detection and Differentiation Porphyromonas gingivalis Treponema denticola Tannerella Forsythia and Fusobacterium nucleatum RNA Detection Qualitative Test sale cost 1950 AED Periodontal Multiplex Detection and Differentiation Porphyromonas gingivalis Treponema denticola Tannerella Forsythia and Fusobacterium nucleatum RNA Detection Qualitative Test 2,600 د.إ Original price was: 2,600 د.إ.1,950 د.إCurrent price is: 1,950 د.إ.
BCR-ABL Minor Quantitative Test sale cost 2040 AED BCR-ABL Minor Quantitative Test 2,400 د.إ Original price was: 2,400 د.إ.2,040 د.إCurrent price is: 2,040 د.إ.
Sale!

BCR-ABL Major Quantitative Test

Original price was: 2,400 د.إ.Current price is: 1,800 د.إ.

-25%

The BCR-ABL Major Quantitative Test is a crucial diagnostic and monitoring tool used in the management of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). This test specifically measures the amount of BCR-ABL fusion gene transcript in the blood or bone marrow. The presence of this gene results from a chromosomal abnormality known as the Philadelphia chromosome, which is a hallmark of CML and can also be present in ALL patients.

The test employs quantitative real-time PCR technology, allowing for the precise quantification of BCR-ABL gene transcripts. This level of precision is vital for assessing the disease’s progression, evaluating patient response to therapy, and detecting minimal residual disease that may indicate a relapse.

At DNA Labs UAE, the BCR-ABL Major Quantitative Test is offered at a cost of 1800 AED. DNA Labs UAE is equipped with state-of-the-art facilities and employs highly skilled professionals to ensure the accuracy and reliability of test results. This test is a key component in the personalized treatment plans for leukemia patients, enabling healthcare providers to tailor therapies based on the genetic profile of the individual’s disease and monitor their response over time.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

BCRABL Major Quantitative Test

Cost: AED 1800.0

Symptoms and Diagnosis

The BCRABL Major Quantitative Test is a laboratory test used to monitor and assess the response to treatment in patients with chronic myeloid leukemia (CML). CML is a type of cancer that affects the bone marrow and causes an overproduction of white blood cells.

The BCR/ABL gene, which is found in the majority of CML patients, produces a protein called BCR/ABL tyrosine kinase. This protein plays a crucial role in the development and progression of CML.

The test measures the amount of BCR/ABL transcripts (mRNA) in the patient’s blood or bone marrow. It uses a technique called real-time polymerase chain reaction (RT-PCR) to amplify and detect the BCR/ABL mRNA.

The results of the test are reported as a ratio of BCR/ABL transcripts to a reference gene, usually ABL or GUS. This ratio is compared to the baseline level before treatment or a standardized control to determine the response to treatment. A decrease in the BCR/ABL ratio indicates a positive response to treatment, while an increase or stable ratio may indicate resistance or lack of response to treatment.

Test Details

  • Components: BCRABL Major Quantitative Test
  • Price: AED 1800.0
  • Sample Condition: Whole Blood, Culture Cells, Bone marrow aspirations
  • Report Delivery: 3rd Working Day Email: 36 hours, On phone: 24 hours
  • Method: Real Time PCR
  • Test Type: Viral
  • Doctor: Physician
  • Test Department: Genetics
  • Pre Test Information: Need to sign Consent document and bring any clinical history of patient for BCR/ABL Major Quantitative Test

Importance in CML Management

The BCR/ABL Major Quantitative Test is an important tool in the management of CML. It helps guide treatment decisions and predicts the prognosis of the disease. The test is typically performed at regular intervals during treatment to monitor the patient’s response and adjust the treatment plan accordingly.

By monitoring the BCR/ABL ratio over time, doctors can assess the effectiveness of the treatment and make adjustments if necessary. A decrease in the ratio indicates a positive response to treatment, while an increase or stable ratio may indicate resistance or lack of response to treatment.

Overall, the BCR/ABL Major Quantitative Test plays a crucial role in the monitoring and assessment of CML patients, allowing for personalized and effective treatment plans.

Test Name BCRABL Major Quantitative Test
Components
Price 1800.0 AED
Sample Condition Whole Blood, Culture Cells, Bone marrow aspirations,
Report Delivery 3rd Working Day Email:-36 hours.On phone: 24 hours
Method Real Time PCR
Test type Viral
Doctor Physician
Test Department: Genetics
Pre Test Information Need to sign Consent document and bring any clinical history of patient forBCR/ABL Major QuantitativeTest
Test Details

The BCR/ABL major quantitative test is a laboratory test used to monitor and assess the response to treatment in patients with chronic myeloid leukemia (CML). CML is a type of cancer that affects the bone marrow and causes an overproduction of white blood cells.

The BCR/ABL gene is a genetic abnormality that is found in the majority of CML patients. This abnormal gene produces a protein called BCR/ABL tyrosine kinase, which plays a crucial role in the development and progression of CML.

The BCR/ABL major quantitative test measures the amount of BCR/ABL transcripts (mRNA) in the patient’s blood or bone marrow. The test uses a technique called real-time polymerase chain reaction (RT-PCR) to amplify and detect the BCR/ABL mRNA.

The results of the BCR/ABL major quantitative test are reported as a ratio of BCR/ABL transcripts to a reference gene (usually ABL or GUS). This ratio is then compared to the baseline level before treatment or to a standardized control to determine the response to treatment.

A decrease in the BCR/ABL ratio indicates a positive response to treatment, while an increase or stable ratio may indicate resistance or lack of response to treatment. Monitoring the BCR/ABL ratio over time allows doctors to assess the effectiveness of the treatment and make adjustments if necessary.

The BCR/ABL major quantitative test is an important tool in the management of CML, as it helps guide treatment decisions and predicts the prognosis of the disease. It is typically performed at regular intervals during treatment to monitor the patient’s response and adjust the treatment plan accordingly.

SKU: TEST-5008 Category:

Related products